PharmaCyte Biotech, Inc. (PMCB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 04-30. Amounts in USD.

Revenue Quarterly

-20K 0 20K 40K 60K Q1 '11: 27K Q2 '11: 15.9K Q3 '11: 32K Q4 '11: 51.1K Q1 '12: 19.8K Q2 '12: 19.8K Q3 '12: 20.3K Q4 '12: 6.7K Q1 '13: 6.6K Q2 '13: 6.3K Q3 '13: 0 Q4 '13: -753 Q1 '14: 0 Q2 '14: 0 Q3 '14: 0 Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q3 '26: 0 Q4 '26: 0 Q4 '12 Q4 '14 Q4 '16 Q4 '18 Q4 '20 Q4 '22 Q4 '24 Q4 '26

Gross Profit Quarterly

-20K 0 20K 40K 60K Q1 '11: 20K Q2 '11: 13K Q3 '11: 10K Q4 '11: 50.8K Q1 '12: 4.1K Q2 '12: 13.8K Q3 '12: 18.1K Q4 '12: 11.2K Q1 '13: 6.6K Q2 '13: -3.3K Q3 '13: 0 Q4 '13: -753 Q1 '14: 0 Q2 '14: 0 Q3 '14: 0 Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q4 '11 Q4 '12 Q4 '13 Q4 '14 Q4 '15 Q4 '16 Q4 '17

Operating Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q1 '12: -652.6K Q2 '12: -403.7K Q3 '12: -410K Q4 '12: -482.9K Q1 '13: -538.8K Q2 '13: -348.8K Q3 '13: -340.8K Q4 '13: -455.2K Q1 '14: -1.4M Q2 '14: -448.6K Q3 '14: -681.1K Q4 '14: -16.4M Q1 '15: -1.6M Q2 '15: -6.2M Q3 '15: -1.5M Q4 '15: -4M Q1 '16: -1.5M Q2 '16: -1.6M Q3 '16: -1.8M Q4 '16: -1.1M Q1 '17: -1M Q2 '17: -974.2K Q3 '17: -1.3M Q4 '17: -1.2M Q1 '18: -1.7M Q2 '18: -1.8M Q3 '18: -2M Q4 '18: -1.4M Q1 '19: -1.2M Q2 '19: -1M Q3 '19: -676.3K Q4 '19: -1.2M Q1 '20: -1.1M Q2 '20: -1.1M Q3 '20: -875.3K Q4 '20: -749.9K Q1 '21: -881.7K Q2 '21: -949.5K Q3 '21: -756.8K Q4 '21: -1M Q1 '22: -1M Q2 '22: -1M Q3 '22: -856.1K Q4 '22: -1.5M Q1 '23: -1.7M Q2 '23: -2.3M Q3 '23: -1.6M Q4 '23: -903.3K Q1 '24: -2.1M Q2 '24: -1.4M Q3 '24: -1.9M Q4 '24: -3.2M Q1 '25: -1.3M Q2 '25: -1.1M Q3 '25: -960.3K Q4 '25: -1M Q1 '26: -848.3K Q2 '26: -1.4M Q3 '26: -2.1M Q4 '26: -2.5M Q4 '12 Q4 '14 Q4 '16 Q4 '18 Q4 '20 Q4 '22 Q4 '24 Q4 '26

Net Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '11: -134.3K Q2 '11: -45.8K Q3 '11: -124.1K Q4 '11: -1.1M Q1 '12: -686K Q2 '12: -437.2K Q3 '12: -271.8K Q4 '12: -504.4K Q1 '13: -510.5K Q2 '13: -382.8K Q3 '13: -376.8K Q4 '13: -327.2K Q1 '14: -4.7M Q2 '14: -5.7M Q3 '14: -458.8K Q4 '14: -16.5M Q1 '15: -1.6M Q2 '15: -4.1M Q3 '15: -1.5M Q4 '15: -4M Q1 '16: -1.5M Q2 '16: -1.6M Q3 '16: -1.8M Q4 '16: -1.1M Q1 '17: -1M Q2 '17: -974.6K Q3 '17: -1.3M Q4 '17: -1.2M Q1 '18: -1.7M Q2 '18: -1.8M Q3 '18: -2M Q4 '18: -1.3M Q1 '19: -1.2M Q2 '19: -1M Q3 '19: -676.3K Q4 '19: -1.1M Q1 '20: -1.1M Q2 '20: -1.1M Q3 '20: -875.3K Q4 '20: -750.4K Q1 '21: -883.9K Q2 '21: -950.2K Q3 '21: -757.1K Q4 '21: -960K Q1 '22: -1M Q2 '22: -979.7K Q3 '22: -811.3K Q4 '22: -1.4M Q1 '23: -1.5M Q2 '23: -1.9M Q3 '23: -764.1K Q4 '23: -126.3K Q1 '24: -3.2M Q2 '24: 2.8M Q3 '24: -619.5K Q4 '24: -2.5M Q1 '25: 23.4M Q2 '25: -1.5M Q3 '25: -3M Q4 '25: 11.7M Q1 '26: -8.4M Q2 '26: -7.4M Q3 '26: 746.9K Q4 '26: -4.4M Q4 '12 Q4 '14 Q4 '16 Q4 '18 Q4 '20 Q4 '22 Q4 '24 Q4 '26

Cost of Revenue Quarterly

0 8K 16K 24K Q1 '11: 6.9K Q2 '11: 2.9K Q3 '11: 22K Q4 '11: 343 Q1 '12: 15.7K Q2 '12: 6K Q3 '12: 2.2K Q1 '13: 0 Q2 '13: 9.6K Q3 '13: 0 Q4 '13: 0 Q1 '14: 0 Q2 '14: 0 Q3 '14: 0 Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q3 '11 Q3 '12 Q4 '13 Q4 '14 Q4 '15 Q4 '16 Q4 '17

Operating Cash Flow Quarterly

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q1 '11: -13.2K Q2 '11: -1.3K Q3 '11: -68.9K Q4 '11: -141.9K Q1 '12: -119.6K Q2 '12: -51.6K Q3 '12: -36.1K Q4 '12: -52K Q1 '13: -85.4K Q2 '13: -84.5K Q3 '13: -77.6K Q4 '13: -143K Q1 '14: -159.7K Q2 '14: -207.1K Q3 '14: -249.7K Q4 '14: -938.2K Q1 '15: -786.8K Q2 '15: -1.6M Q3 '15: -1.1M Q4 '15: -1.1M Q1 '16: -1.1M Q2 '16: -1.1M Q3 '16: -1M Q4 '16: -1.2M Q1 '17: -906.9K Q2 '17: -706.3K Q3 '17: -925.3K Q4 '17: -800.9K Q1 '18: -935.6K Q2 '18: -1.6M Q3 '18: -1.2M Q4 '18: -1.4M Q1 '19: -622.2K Q2 '19: -917.8K Q3 '19: -676.5K Q4 '19: -661.4K Q1 '20: -763.1K Q2 '20: -583.6K Q3 '20: -352.2K Q4 '20: -639.4K Q1 '21: -551K Q2 '21: -1.3M Q3 '21: -589.1K Q4 '21: -940.3K Q1 '22: -1.2M Q2 '22: -1.4M Q3 '22: -298.6K Q4 '22: -1.2M Q1 '23: -1.1M Q2 '23: -1.9M Q3 '23: -541.7K Q4 '23: -288.4K Q1 '24: 343K Q2 '24: -2M Q3 '24: -177.1K Q4 '24: -333K Q1 '25: -373.3K Q2 '25: -1.1M Q3 '25: -509.9K Q4 '25: -1M Q1 '26: -2M Q2 '26: -979.5K Q3 '26: -786.8K Q4 '26: -1.4M Q4 '12 Q4 '14 Q4 '16 Q4 '18 Q4 '20 Q4 '22 Q4 '24 Q4 '26

Free Cash Flow Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 500M 1B 1.5B Q1 '11: 348.4M Q2 '11: 348.4M Q3 '11: 348.4M Q1 '12: 367.3M Q2 '12: 374.1M Q3 '12: 373.3M Q1 '13: 419.6M Q2 '13: 429.5M Q3 '13: 444.7M Q1 '14: 521.9M Q2 '14: 541.2M Q3 '14: 599.9M Q1 '15: 701.9M Q2 '15: 703.3M Q3 '15: 696.1M Q1 '16: 737.9M Q2 '16: 745.4M Q3 '16: 756.6M Q1 '17: 788.2M Q2 '17: 848.9M Q3 '17: 859.5M Q1 '18: 925.6M Q2 '18: 973.2M Q3 '18: 975.8M Q1 '19: 1B Q2 '19: 1.1B Q3 '19: 1.1B Q1 '20: 1.2B Q2 '20: 1.3B Q3 '20: 1.4B Q1 '21: 1.1M Q2 '21: 1.5M Q3 '21: 1.6M Q1 '22: 1.6M Q2 '22: 17.4M Q3 '22: 21.7M Q1 '23: 20.8M Q2 '23: 20.6M Q3 '23: 19M Q1 '24: 12.6M Q2 '24: 8.8M Q3 '24: 8.6M Q1 '25: 7.9M Q2 '25: 7.6M Q3 '25: 7M Q1 '26: 6.8M Q2 '26: 6.8M Q3 '26: 9.3M Q3 '12 Q3 '14 Q3 '16 Q3 '18 Q3 '20 Q3 '22 Q3 '24 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '11: 0.00 Q1 '12: 0.00 Q2 '12: 0.00 Q3 '12: 0.00 Q4 '12: -0.01 Q1 '13: -0.01 Q2 '13: -0.01 Q3 '13: -0.01 Q4 '13: 0.00 Q1 '14: -0.01 Q2 '14: -0.02 Q3 '14: -0.02 Q4 '14: -0.05 Q1 '15: -0.04 Q2 '15: -0.04 Q3 '15: -0.04 Q4 '15: -0.02 Q1 '16: -0.02 Q2 '16: -0.01 Q3 '16: -0.01 Q4 '16: 0.00 Q1 '17: 0.00 Q2 '17: 0.00 Q3 '17: 0.00 Q4 '17: 0.00 Q1 '18: 0.00 Q2 '18: 0.00 Q3 '18: 0.00 Q4 '18: 0.00 Q1 '19: 0.00 Q2 '19: 0.00 Q3 '19: 0.00 Q4 '19: 0.00 Q1 '20: 0.00 Q2 '20: 0.00 Q3 '20: 0.00 Q4 '20: -4.23 Q1 '21: -5.02 Q2 '21: -5.64 Q3 '21: -6.13 Q4 '21: -2.51 Q1 '22: -2.36 Q2 '22: -1.80 Q3 '22: -1.35 Q4 '23: -0.21 Q1 '24: -0.68 Q2 '24: -0.85 Q3 '25: 0.74 Q4 '25: 2.59 Q1 '26: -0.54 Q2 '26: -1.39 Q3 '26: -1.12 Q4 '26: -3.00 Q3 '12 Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '24 Q4 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.